



**Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
22 – 25 March 2021
Virtual Meeting
Draft Agenda**

Monday, 22 March 2021

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
10:00	Closed SAGE meeting	Preparation of the sessions of the day. Other important discussion items.	1h
11:00	Break	Break	15 min
11:15	Opening and welcome – introduction of participants Opening: Director-General WHO. 5min. Welcome: A. CRAVIOTO. Chair of SAGE. 10 min.	Opening of the Plenary Meeting	15 min.
11:30	Global and Regional Reports – Session 1 Report from the Director of IVB. K. O'BRIEN. WHO. 20 min. Reports from the Regions – including impact of the COVID-19 pandemic and COVID-19 vaccination on immunization services. 60 min. Update from Gavi. S. BERKLEY. GAVI. 10 min. Discussion. 30 min.	FOR INFORMATION	2h
13:30	Break	Break	30 min.
14:00	Ebola vaccines – Session 2	FOR RECOMMENDATION	2h
16:00	End of the day		

Tuesday, 23 March 2021

10:00	Closed SAGE meeting	Preparation of the sessions of the day. Recap of day 1. Other important discussion items.	1h
11:00	Break	Break	15 min.
11:15	COVID-19 Vaccines – Session 3 (part 1)	FOR RECOMMENDATION	2h min.
13:15	Break	Break	30 min.
13:45	COVID-19 Vaccines – Session 3 (part 2)		1h
14:45	COVID-19 Post introduction considerations – Session 4		
14:45	COVID-19 variants – Session 4a	FOR DISCUSSION	30 min.
	Presentation (TBC). 10 min.		
	Discussion: 20 min.		
15:15	COVID-19 Vaccination - Early learnings – Session 4b	FOR DISCUSSION	1h
16:15	COVID-19 Vaccine Safety – Session 4c	FOR DISCUSSION	30 min.
	Presentation by WHO Safety team/GACVS. 15 min.		
	Discussion. 30 min		
16:45	End of the day		

Wednesday, 24 March 2021

10:00	Closed SAGE meeting	Preparation of the sessions of the day. Recap of day 2. Other important discussion items.	1h
11:00	Break	Break	15 min.
11:15	Polio – Session 5	FOR RECOMMENDATION	1h 30 min.
	Update from the Global Polio Eradication Initiative. A.O'LEARY. WHO. 15 min.	SAGE will be informed on the current status of the polio eradication program in the context of COVID 19; and nOPV2 first use experience.	
	Questions: 10 min.		
	Update on nOPV2 first use, safety oversight, transition plan from initial to wider nOPV2 use including results from modelling of delay in response to cVDPV2 outbreak. S. ZIPURSKI, G. MACKLIN, O.MACH, WHO. 20 min.	SAGE will be asked to review and consider for endorsement:	
	Questions: 15 min.	<ul style="list-style-type: none"> • Endorse recommendation on sIPV use in polio programme • Endorse recommendation on transition from initial to wider nOPV2 use • Provide recommendation on benefit of immediate response with mOPV2 versus delayed response with nOPV 	
	Report from SAGE Polio Working Group including considerations for sIPV use I. JANI, SAGE Member. 15 min.		
	Discussion: 15 min.		
12:45	Break	Break	30 min.

13:15	Vaccine acceptance and uptake – Session 6	FOR DISCUSSION	1h
	<p>Introduction and framing – SAGE member. 5 min.</p> <p>Updates on the latest trends and evidence – J. Leask. 15 min.</p> <p>WHO key activities for 2021-2022 and proposed plan of work – L. Menning, WHO. 10 min.</p> <p>Discussion. 30 min.</p>	<p>The objectives of the session are:</p> <ul style="list-style-type: none"> • To update SAGE on the latest evidence and developments for acceptance and uptake in the behavioural sciences field, including: key interventions supported by the evidence, concepts and terminology, WHO's role and key activities • To present a plan of work to develop an evidence-based approach to measuring and addressing behavioural and social drivers of uptake, including corresponding interventions for action. • To invite SAGE feedback on the approach to gathering and using behavioural sciences data. <p>Questions posed to SAGE:</p> <ul style="list-style-type: none"> - Does SAGE agree with the proposed plan of work? - Are there any considerations or resources or methods which should be incorporated? 	
14:15	Measles Rubella – Session 7	FOR DISCUSSION	1h
	<p>Introduction presentation: History of what SAGE MR WG has achieved, Feasibility Assessment, Pivots in direction</p> <p>Presentation of Measles epidemiology and progress to MR elimination</p> <p>Discussion.</p>		
15:15	Closing		15 min.
15:30	End of the Plenary Meeting		

Thursday, 25 March 2021

12:00	Closed SAGE meeting	Recap of day 3. Other important discussion items.	2h
14:00	End of the meeting		